Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery

NCT00858936 | Terminated Phase 2 DMC

• 1 other identifier: S201
• Study Type: interventional
• Target: 6
• Locations: 2 countries
• Sites: 8

Brief Summary

This clinical trial will investigate the safety and effectiveness of IK-1001 (the liquid form of sodium sulfide) when used in Coronary Artery Bypass Graft (CABG) patients to potentially reduce the damage done to the heart during surgery. This study has 2 parts. Part 1 will first test 36 subjects at different doses (amount) of the study drug. There will be 6 different groups of 6 subjects each that will receive the study drug or a placebo. A placebo is a substance that will be prepared to look like the study drug but will contain no active ingredients. In Part 1, five subjects from each group will receive study drug (IK-1001) and one will receive a placebo. This first part of this study is also a dose (amount) escalation. This means that each group will be receiving a different dose of the study drug. The first group will receive the lowest dose, the second group will receive a slightly higher dose, and the third group a slightly higher dose until all six groups has been tested. You can not choose which group you will be in but prior to starting each new dose level, the data (information) from the previous dose level will have been reviewed by a group of qualified individuals to determine if it is safe to proceed to the next highest dose level. Part 2 will expand the study and will treat at least 158 (and up to 632) more subjects at a dose level that has been deemed safe from information collected from Part 1. Subjects in Part 2 of the study will have a 1 in 2 (50%) chance of receiving the study drug or placebo. Whether the subject gets study drug or the placebo will be randomly assigned (like the toss of a coin). The study drug or placebo will be given as an intravenous infusion (into the vein) for six hours while the subject is having their CABG surgery. The subjects will be followed up for 6 months after their CABG surgery.

Conditions

Coronary Artery Bypass Surgery

Keywords

CABG(coronary artery bypass graft); Ischemia; Heart surgery; Heart damage

Outcome Measures

Primary Outcomes (1)

• Cardiac Troponin T

  Day 1 through Day 4

Secondary Outcomes (9)

• Mortality

  Study duration

• 12-Lead ECG

  Periodically through study duration

• Urinalysis

  Screening, and 6 month

• Echocardiography

  Screening, 3 month and 6 month

• Blood Draws

  Study duration

Study Arms (2)

IK-1001

EXPERIMENTAL

6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours

Drug: IK-1001

Normal Saline

PLACEBO COMPARATOR

6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours

Drug: Normal Saline

Interventions

IK-1001 DRUG

6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours

IK-1001

Normal Saline DRUG

6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours

Normal Saline

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be 18 to 85 years of age
• Subject is scheduled to undergo CABG surgery with cardiopulmonary bypass
• Subjects at an increased risk for I/R mediated tissue damage: defined as subjects with ≥ 30% but ≤ 50% ejection fraction (as measured by echocardiography within 14 days of study enrollment) or who fulfill at least two of the following criteria:
• Current or recent smoker (within last 6 months prior to screening)
• Female
• Diabetes mellitus (a history of diabetes, regardless of duration of disease or need for anti-diabetic agents)
• History of non-disabling stroke, TIA, carotid endarterectomy
• Re- CABG (H/O previous CABG surgery, on or off-pump)
• Peripheral artery surgery or angioplasty
• Recent MI (≥ 48 hours and ≤ 6 weeks before surgery, non STEMI and STEMI infarcts as documented in the medical records of the subject)
• History of congestive heart failure (NYHA CHF Class III or IV)
• Renal dysfunction: creatinine clearance ≥ 30mL/min but \< 60mL/min calculated using Crockroft and Gault formula: Creatinine clearance (mL/min) = (140 - age) x weight (kg) (x 0.85 for females) (72 x serum creatinine)
• Asymptomatic stenosis (≥ 50%) in ≥ 1 carotid artery
• Age \> 65 years

You may not qualify if:

• Known sulfite allergy or sulphur drug allergy
• Subjects who have received treatment for asthma within the past 12 months
• Myocardial infarction occurring \< 48 hours prior to surgery
• Current cardiogenic shock, acute left ventricular rupture, ventricular septal rupture, or papillary muscle rupture
• History of prior disabling stroke
• Clinically relevant liver disease (defined as serum transaminases ≥ 3 x upper limit of normal for local laboratory)
• Poorly controlled diabetes mellitus (defined as HbA1c \> 9.0%)
• Planned concomitant cardiac valve or other surgery at time of CABG
• Planned use of thiopental during anesthesia for CABG surgery
• All females of child bearing potential (defined as having menses without an alternative medical cause during the last 12 months). Women who are pregnant (defined as a positive serum pregnancy test), breast-feeding or lactating are also excluded.
• Ongoing alcohol or drug abuse
• Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study
• Subject has participated in another investigational drug or device study within 30 days prior to enrollment to the study.

Sponsors & Collaborators

• Mallinckrodt: lead

Study Sites (8)

Ashford Hospital

Ashford, South Australia, 5035, Australia

Location

Flinder Medical Center

Bedford Park, South Australia, 5042, Australia

Location

Austin Hospital

Heidelberg, Victoria, 3084, Australia

Location

Alfred Hospital

Melbourne, Victoria, 3004, Australia

Location

St. Vincents Hospital

Melbourne, Victoria, Australia

Location

Boniface General Hospital

Winnepeg, Manitoba, R2H 2A6, Canada

Location

Royal Victoria Hospital - MUHC

Montreal, Quebec, H3A 1A1, Canada

Location

Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada

Location

MeSH Terms

Conditions

Ischemia

Interventions

Saline Solution

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Crystalloid Solutions; Isotonic Solutions; Solutions; Pharmaceutical Preparations

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 9, 2009
• First Posted: March 10, 2009
• Study Start: May 1, 2009
• Primary Completion: April 1, 2010
• Study Completion: April 1, 2010
• Last Updated: October 19, 2016

Record last verified: 2016-10

Locations

AU (5); CA (3)